Prognostic factors for overall and event-free survival by univariate and multivariate analyses
| Variables . | Effect on OS . | P . | Effect on EFS . | P . |
|---|---|---|---|---|
| Sex | NS | NS | ||
| Duration on imatinib, longer | favorable | .01 | favorable | < .001 |
| CML duration | NS | NS | ||
| Age | favorable | .03 | NS | |
| Nilotinib versus dasatinib | NS | NS | ||
| Leukocytes | NS | NS | ||
| Neutrophils | NS | NS | ||
| Hemoglobin, higher | favorable | < .001 | favorable | .02 |
| Platelets, higher | favorable | < .001 | favorable | .002 |
| Peripheral basophils %, higher | NS | NS | ||
| Peripheral blasts %, higher | unfavorable | < .001 | unfavorable | < .001 |
| Marrow basophils %, higher | NS | NS | ||
| Marrow blast %, higher | unfavorable | < .001 | unfavorable | < .001 |
| Clonal evolution, yes | NS | NS | ||
| % Ph+ at second-generation TKI start | NS | NS | ||
| Stage at second-generation TKI BP/ALL (vs AP) | unfavorable | < .001 | unfavorable | < .001 |
| Response to TKI (MCyR+CHRc vs all others) | favorable | < .001 | favorable | < .001 |
| Variables . | Effect on OS . | P . | Effect on EFS . | P . |
|---|---|---|---|---|
| Sex | NS | NS | ||
| Duration on imatinib, longer | favorable | .01 | favorable | < .001 |
| CML duration | NS | NS | ||
| Age | favorable | .03 | NS | |
| Nilotinib versus dasatinib | NS | NS | ||
| Leukocytes | NS | NS | ||
| Neutrophils | NS | NS | ||
| Hemoglobin, higher | favorable | < .001 | favorable | .02 |
| Platelets, higher | favorable | < .001 | favorable | .002 |
| Peripheral basophils %, higher | NS | NS | ||
| Peripheral blasts %, higher | unfavorable | < .001 | unfavorable | < .001 |
| Marrow basophils %, higher | NS | NS | ||
| Marrow blast %, higher | unfavorable | < .001 | unfavorable | < .001 |
| Clonal evolution, yes | NS | NS | ||
| % Ph+ at second-generation TKI start | NS | NS | ||
| Stage at second-generation TKI BP/ALL (vs AP) | unfavorable | < .001 | unfavorable | < .001 |
| Response to TKI (MCyR+CHRc vs all others) | favorable | < .001 | favorable | < .001 |
MCyR+CHR c indicates MCyR with a concomitant CHR; and NS, not significant.